Association of the use of nonfood prebiotics, probiotics, and synbiotics with total and cause-specific mortality: a prospective cohort study
- PMID: 40114150
- PMCID: PMC11924732
- DOI: 10.1186/s12937-025-01104-w
Association of the use of nonfood prebiotics, probiotics, and synbiotics with total and cause-specific mortality: a prospective cohort study
Abstract
Background: The use of nonfood prebiotics, probiotics, and synbiotics has approximately tripled in the last 20 years. It is necessary to examine the associations of these substances with all-cause and cause-specific mortality in a large prospective cohort.
Methods: This study included 53,333 adults from the National Health and Nutrition Examination Survey 1999-2018. All participants answered questions on the use of dietary supplements and medications, including prebiotics, probiotics, and synbiotics. Death outcomes were determined by linkage to National Death Index records through 31 December 2019. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for mortality from all causes, heart diseases, cancer, and other causes.
Results: During a mean follow-up of 10.6 years, 9117 deaths were documented, including 2364 heart disease deaths, 1964 cancer deaths, and 4700 other causes deaths. Compared to nonusers, nonfood prebiotic, probiotic, and synbiotic users had a 59% (HR 0.41, 95% CI 0.30 to 0.56), 56% (HR 0.44, 95% CI 0.26 to 0.74), 49% (HR 0.51, 95% CI 0.31 to 0.83), and 64% (HR 0.36, 95% CI 0.23 to 0.59) for lower risk of all-cause, cancer, heart disease, and other causes mortality, respectively. Moreover, the inverse association of the use of prebiotics, probiotics, and synbiotics with mortality was stronger in female participants and participants without hypertension.
Conclusion: The use of nonfood prebiotics, probiotics, and synbiotics is significantly associated with lower all-cause mortality, as well as deaths from heart disease, cancer, and other causes.
Keywords: Mortality; Nonfood; Prebiotics; Probiotics; Synbiotics.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study protocol for the US NHANES was approved by the US NHANES institutional review board and National Center for Health Statistics Research ethics review board. Institutional review board approval was waived for this analysis because of the publicly available and deidentified data. Competing interests: The authors declare no competing interests.
Figures


References
-
- Gibson GR, Hutkins R, Sanders ME et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017;14:491–502. England. - PubMed
-
- Hill C, Guarner F, Reid G, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–14. England:. - PubMed
MeSH terms
Substances
Grants and funding
- 2022RC017/Zhejiang University K. P. Chao's High Technology Development Foundation
- 2018ZX10721102-003-006, 2018ZX10715013-003-003/Mega-Project of National Science and Technology for the 13th Five-Year Plan of China
- K20210205, 2022ZFJH003/Fundamental Research Funds for the Central Universities
- 2020R52010/Technological Innovation Leading Talents of "Ten Thousand Talents Plan" of Zhejiang Province
- 71904170/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources